Young Cancer Survivors Have Increased Risk for HPV-Linked Subsequent Cancer
Significantly increased risk seen for any HPV-associated subsequent malignant neoplasms and oropharyngeal neoplasms.
Diagnosis & Disease Information
Rozlytrek, a Tumor Agnostic Therapy, Receives FDA Approval
The Food and Drug Administration (FDA) has granted accelerated approval to Rozlytrek (entrectinib; Genentech)
Kaposi Sarcoma Treatment Gets Breakthrough Therapy Designation
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Pomalyst (pomalidomide; Celgene) for the treatment of patients with Kaposi sarcoma.
Vincristine
This slideshow reviews vincristine, indicated for Hodgkin disease, Kaposi sarcoma, leukemia, neuroblastoma, non-Hodgkin lymphoma, rhabdomyosarcoma, and Wilms’ tumor.
A roundup of FDA oncology news from October 2013
The FDA asked the manufacturer of ponatinib (Iclusig) to suspend marketing and sales of the drug, hydrocodone bitartrate extended-release capsules (Zohydro ER) gained FDA approval, and other FDA actions.
Doxil shortage speeds approval of generic version
After expedited review, the FDA okays the first generic version of Doxil (doxorubicin hydrochloride liposome injection), now in short supply.
Clinical Trial: Pomalidomide for Kaposi Sarcoma in People With or Without HIV
Clinical Trial: Pomalidomide for Kaposi Sarcoma in People With or Without HIV Sponsor and CollaboratorsNational Cancer Institute (NCI) Principal InvestigatorRobert Yarchoan, MD, National Cancer Institute (NCI) ClinicalTrials.gov IdentifierNCT01495598Continue Reading
Cutaneous melanoma begets cutaneous melanoma
Continued skin surveillance is important for survivors of cutaneous melanoma (CM), indicate findings showing that this is the most common second primary cancer among persons with a first CM.
- Loading...
Loading...
Loading... 
Loading...